BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8753738)

  • 1. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
    Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
    Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
    Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
    Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
    Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
    Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
    Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; TĂȘtu B
    Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
    Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
    J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma.
    Papadopoulos I; Rudolph P; Weichert-Jacobsen K
    Eur Urol; 1997; 32(1):110-7. PubMed ID: 9266242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
    Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [P53 expression and its clinical significance in prostatic carcinoma].
    Jiang T; Jiang H; Song XS; Li XC; Li QL
    Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.